Financial Performance - The company's operating revenue for 2022 was CNY 15,372,423,363.17, representing a 5.27% increase from CNY 14,603,100,739.78 in 2021[19] - The net profit attributable to shareholders of the listed company for 2022 was CNY 1,425,811,705.31, an increase of 16.17% compared to CNY 1,227,372,820.22 in 2021[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,398,575,430.62, up 15.67% from CNY 1,209,084,450.63 in the previous year[19] - Basic earnings per share rose by 16.20% to CNY 1.040 in 2022 compared to CNY 0.895 in 2021[20] - The weighted average return on equity increased by 0.72 percentage points to 12.71% in 2022 from 11.99% in 2021[20] - The gross profit margin improved to 48.80%, up by 1.18 percentage points compared to the previous year[32] - The total pre-tax compensation for the board members amounted to 1,067.37 million CNY for the reporting period[104] Cash Flow and Assets - The net cash flow from operating activities was CNY 3,094,296,284.27, a decrease of 9.69% from CNY 3,426,414,563.66 in 2021[19] - Total assets increased by 7.86% to CNY 27,044,491,889.50 in 2022 from CNY 25,072,835,362.31 in 2021[20] - The net cash flow from operating activities decreased by 9.69% year-on-year, amounting to 3,094.30 million yuan, mainly due to increased cash payments for goods and services[48] - The net increase in cash and cash equivalents was 1,735.40 million yuan, reflecting a 5.16% increase compared to the previous year[48] - Cash and cash equivalents amounted to ¥4,872,001,806.53 in 2022, an increase from ¥3,927,134,045.02 in 2021, marking a rise of about 24.0%[198] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.2 per 10 shares (including tax) based on a total share capital of 1,371,470,262 shares[4] - The company distributed a cash dividend of CNY 397,726,375.98, which accounts for 32.40% of the net profit attributable to ordinary shareholders in the consolidated financial statements[134] - The cash dividend per 10 shares is CNY 2.9, with no bonus shares or capital increase from reserves proposed[134] - The company has maintained a stable and continuous return policy for shareholders, considering future funding needs[132] Risk Management and Compliance - The company did not face any significant risks that could materially affect its operations during the reporting period[6] - The company has established a comprehensive integrity and compliance mechanism, including the formation of an Integrity and Compliance Committee and the implementation of risk assessment and feedback mechanisms[27] - The company emphasizes the importance of risk awareness regarding forward-looking statements in its report[5] - The company is facing risks related to industry policy changes, raw material supply fluctuations, and market instability, and is adapting its strategies accordingly[94] - The company is committed to maintaining high-quality standards in drug production and is enhancing its procurement processes to mitigate risks associated with raw material quality[94] Research and Development - Research and development expenses increased by 23.59% to CNY 217,446,263.51, indicating a significant investment in innovation[32] - The total R&D investment amounted to 3,660.83 million yuan, representing 2.38% of operating revenue, with a year-on-year increase of 14.50%[44] - The R&D team has made progress in new product development, including classic formulas and quality standards, with a focus on enhancing product value and addressing resource scarcity issues[65] - The company is actively pursuing internationalization of traditional Chinese medicine, particularly in the Hong Kong market, by enhancing marketing reforms and multi-channel promotion[28] - The company is focused on enhancing its product portfolio through strategic R&D initiatives and exploring market opportunities[65] Market Expansion and Retail Strategy - The company plans to continue focusing on market expansion and new product development to drive future growth[20] - As of the end of the reporting period, the company had 942 retail stores, focusing on enhancing operational efficiency and new retail technology to improve overall service levels[25] - The company has expanded its retail network to 73 stores globally, covering major countries and regions in Asia, Oceania, North America, and Europe[28] - The company is focusing on market demand and consumer trends, emphasizing marketing innovation and precise promotion strategies[57] Corporate Governance - The company has established an independent financial accounting department and a financial management system, ensuring independent financial decision-making[98] - The company’s management team is fully independent, with no overlapping positions with the controlling shareholder, ensuring transparency in personnel management[99] - The company’s governance structure includes various committees, such as the Strategic and Investment Committee and the Audit Committee, to ensure effective oversight[96] - The company has committed to enhancing its compliance management and legal support systems to foster a culture of integrity and compliance[99] Environmental Responsibility - The company has completed carbon emission verification and compliance tasks for 2021, demonstrating its commitment to environmental responsibility[27] - The company has invested CNY 20.84 million in environmental protection during the reporting period[142] - The company has achieved a total carbon emission of 20,516 tons for the year 2021, fulfilling its carbon emission quota in Beijing[153] - The company has implemented energy-saving management and new technologies to strengthen carbon emission management[155] Employee Development - The company emphasizes talent development through a diversified training system, focusing on management, professional technical, and high-skilled personnel[129] - The company has implemented a salary and assessment system for its management team to enhance performance motivation[136] - The company organizes annual continuing education training for professional technical personnel to strengthen their skills and knowledge[131] Shareholder Information - The total number of ordinary shareholders increased to 84,241 by the end of the reporting period, up from 77,597 at the end of the previous month[177] - The largest shareholder, China Beijing Tongrentang (Group) Co., Ltd., holds 719,308,540 shares, accounting for 52.45% of the total shares[178] - The company has no controlling shareholder or actual controller changes during the reporting period[182]

证券代码：600085 证券简称：同仁堂 公告编号：2023-012 北京同仁堂股份有限公司 关于召开 2022 年年度网络业绩说明会的预告公告 投资者可以在 2023 年 4 月 4 日下午 16:00 前将需要了解的情况和关注问题预 先发送到北京同仁堂股份有限公司（以下简称"同仁堂"或"公司"）邮箱，公 司将在说明会上就投资者普遍关注的问题进行回答。 公司于 2023 年 3 月 28 日披露了《同仁堂 2022 年年度报告》，为便于广大投 资者更全面深入地了解公司 2022 年年度经营成果及财务状况，公司决定于 2023 年 4 月 6 日通过上海证券报·中国证券网 http://roadshow.cnstock.com/召开"同仁 堂 2022 年年度网络业绩说明会"。 一、 说明会类型 本次投资者说明会以网络互动方式召开，公司将针对 2022 年年度的经营成 果及财务指标的具体情况等与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 召开时间：2023 年 4 月 6 日（星期四） 上午 9:30-10:30 召开地点：上海证券报·中国 ...

Financial Performance - In 2021, the company's operating revenue reached CNY 14,603,100,739.78, representing a year-on-year increase of 13.86% compared to CNY 12,825,879,050.96 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was CNY 1,227,372,820.22, an increase of 19.00% from CNY 1,031,440,914.95 in 2020[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,209,084,450.63, up 19.52% from CNY 1,011,615,144.02 in 2020[21] - The net cash flow from operating activities was CNY 3,426,414,563.66, a significant increase of 57.56% compared to CNY 2,174,631,663.93 in 2020[21] - As of the end of 2021, the total assets amounted to CNY 25,072,835,362.31, reflecting a growth of 14.82% from CNY 21,837,512,362.24 at the end of 2020[21] - The net assets attributable to shareholders of the listed company were CNY 10,633,965,371.99, an increase of 8.16% from CNY 9,831,569,428.09 at the end of 2020[21] - Basic earnings per share for 2021 increased by 19.02% to CNY 0.895 compared to CNY 0.752 in 2020[22] - The weighted average return on equity rose to 11.99%, an increase of 1.17 percentage points from 10.82% in 2020[22] - The comprehensive gross profit margin improved to 47.62%, an increase of 0.58 percentage points from the previous year[44] - The company reported a net profit margin of 9.68%, indicating strong profitability[134] Cash Flow and Investments - The net cash flow from operating activities increased by 57.56% to CNY 3,426,414,563.66 in 2021 from CNY 2,174,631,663.93 in 2020[62] - The net cash flow from investing activities improved, with cash outflows for fixed assets and intangible assets decreasing significantly[63] - The net cash flow from financing activities decreased, primarily due to increased cash payments for debt repayment by subsidiaries[63] - The net increase in cash and cash equivalents rose by 143.07% to CNY 1,650,272,492.17 in 2021 from CNY 678,917,148.70 in 2020[62] - The company reported a significant increase in investment income, rising to 9,343,298.96, a 1458.7% increase from the previous year[55] Revenue and Sales - Total operating revenue for Q4 2021 was CNY 3,919,917,415.37, with a net profit attributable to shareholders of CNY 307,374,143.31[24] - The total revenue for the first quarter of 2021 was CNY 3,706,471,529.65, with a net profit of CNY 318,415,643.66 attributable to shareholders[24] - The company achieved a revenue of 1,291.76 million yuan in 2021, representing a year-on-year growth of 10.37%[38] - Operating profit for the year was 645.35 million yuan, an increase of 5.02% compared to the previous year[38] - Net profit reached 540.32 million yuan, reflecting a year-on-year growth of 7.06%[38] - The company achieved operating revenue of CNY 14,603.1 million in 2021, representing a year-on-year growth of 13.86%[44] Research and Development - Research and development expenses rose by 27.38% to CNY 175.9 million, reflecting increased investment in innovation[46] - The company has developed a new product pipeline focusing on 10 initial varieties based on classic formulas[34] - The company has established a smart monitoring system for medicinal herb planting, enhancing the quality control of raw materials[84] - The company is collaborating with external research institutions to promote the transformation of research results into practical applications[85] - R&D investment accounted for 2.19% of the company's operating revenue during the reporting period, which is lower than the industry average[92] Market and Competition - The company is facing intensified competition as the domestic pharmaceutical market shifts from a seller's market to a buyer's market[40] - The company is actively exploring international markets, particularly in response to the growing demand for traditional Chinese medicine abroad[40] - The company aims to enhance its product portfolio by focusing on clinically valuable and health-functional products, with plans for new product development and introduction[113] - The company is committed to a digital transformation strategy, aiming for standardized data management and integrated supply chain control[116] Corporate Governance - The company has a governance structure that includes independent directors and external supervisors, with no shareholding changes reported for the board members during the reporting period[130] - The company has a clear strategy for maintaining operational independence from its controlling shareholder, ensuring fair market transactions[127] - The company emphasizes the importance of legal compliance and governance, ensuring transparency in shareholder meetings and board operations[123] - The company has a structured process for appointing and electing board members, ensuring compliance with governance standards[145] Environmental Responsibility - The company’s wastewater discharge from its pharmaceutical plant totaled 299,900 tons, with no exceedances reported[174] - The company achieved a total carbon emission of 18,030 tons in 2020, a year-on-year reduction of 8.4%[181] - The company actively participated in carbon emission management and completed a carbon emission rights transaction of 10,000 tons in December 2021[182] - The company’s air pollution control facilities operated normally, with pollutant emissions meeting regulatory standards[176] Future Outlook - Future outlook suggests a projected revenue growth of 15% for the upcoming fiscal year, driven by new product launches and market expansion strategies[134] - The company plans to enhance its investment and acquisition activities to strengthen its market position and optimize resource allocation[115] - The company plans to introduce at least three new products in the next quarter, targeting emerging health trends[134] - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[134]

Financial Performance - The company's operating revenue for the first half of 2019 was approximately ¥7.16 billion, a decrease of 1.52% compared to the same period last year[17]. - The net profit attributable to shareholders was approximately ¥660.69 million, an increase of 3.33% year-on-year[17]. - The net cash flow from operating activities reached approximately ¥1.07 billion, reflecting a growth of 7.88% compared to the previous year[17]. - The total assets at the end of the reporting period amounted to approximately ¥21.16 billion, up 3.33% from the end of the previous year[17]. - The net assets attributable to shareholders increased to approximately ¥9.57 billion, representing a growth of 3.35% year-on-year[17]. - The basic earnings per share for the first half of 2019 was ¥0.482, an increase of 3.43% compared to the same period last year[18]. - The company’s comprehensive gross profit margin stood at 49.37% during the reporting period[27]. - The total operating revenue for the first half of 2019 was CNY 7,156,776,468.66, a decrease of 1.52% compared to CNY 7,267,025,863.90 in the same period of 2018[103]. - The operating profit for the first half of 2019 was CNY 1,319,026,849.21, slightly higher than CNY 1,314,735,543.28 in the previous year[104]. - The total profit for the first half of 2019 was CNY 583,983,519.40, an increase of 9.59% from CNY 533,142,413.77 in the first half of 2018[106]. Revenue and Sales - In the first half of 2019, the company achieved operating revenue of 715,677.65 million RMB, with a net profit attributable to shareholders of 66,068.72 million RMB, reflecting a net profit growth of 9.12%[27]. - Domestic revenue decreased by 3.16% to approximately ¥652.37 million, while overseas revenue increased by 23.54% to approximately ¥58.86 million[41]. - The total number of retail stores for Tongrentang reached 854, with a revenue of 394,833.11 million RMB, showing a year-on-year growth of 0.57%[29]. - The marketing team categorized products into four groups, with the main products like Tongrentang Niuhuang Qingxin Wan and Tongrentang Dahuo Luo Wan driving sales through a joint marketing model[27]. Costs and Expenses - Operating costs decreased by 0.76% to approximately ¥3.62 billion from ¥3.65 billion year-on-year[35]. - Research and development expenses increased by 51.44% to approximately ¥44.50 million, driven by increased investment in scientific research projects[36]. - The company reported a decrease in sales expenses to CNY 1,432,735,714.43 from CNY 1,525,992,402.18 in the same period last year[104]. - The company recorded a decrease in financial expenses, with net financial costs of CNY -11,949,954.90 compared to CNY -8,462,634.84 in the previous year, indicating improved financial management[106]. Assets and Liabilities - The company's total assets reached approximately 15.02 billion, indicating a robust asset base[116]. - The total liabilities rose to CNY 6,139,835,574.50 from CNY 5,948,294,826.51, marking an increase of about 3.2%[97]. - The company's equity attributable to shareholders increased to CNY 9,570,772,568.45 from CNY 9,260,951,252.86, reflecting a growth of approximately 3.3%[97]. - Short-term borrowings decreased to CNY 239,500,000.00 from CNY 365,375,000.00, a reduction of about 34.5%[96]. Risk Management and Compliance - The company faced no significant risks that could materially affect its operations during the reporting period[4]. - The company is committed to adapting to policy changes in the pharmaceutical industry, including compliance with prescription regulations and healthcare payment reforms[22]. - The company faces policy risks due to intensified regulations in the medical and pharmaceutical sectors, which may impact operational models[52]. - The company is enhancing its raw material procurement capabilities to mitigate risks associated with price fluctuations in traditional Chinese medicine materials[53]. Corporate Governance and Shareholder Information - The company has a total of 64,065 common stock shareholders as of the end of the reporting period[80]. - The largest shareholder, Beijing Tongrentang (Group) Co., Ltd., holds 719,308,540 shares, representing 52.4% of the total shares[81]. - The company has not experienced any changes in its share capital structure during the reporting period[78]. - The company appointed new executives, including Di Shubing as General Manager and Wang Tian, Zhang Chaohua, and Chen Jiafu as Deputy General Managers[86]. Social Responsibility and Community Engagement - The company has invested CNY 1 million in the construction of a 2.55 km road project in Wolong Village as part of its poverty alleviation efforts[65]. - The company provided material support worth CNY 30,527.5 for poverty alleviation projects, focusing on industrial development[66]. - The company aims to help 30 low-income households in Wolong Village achieve poverty alleviation by the end of 2019[68]. - The company has established a support mechanism for poverty alleviation, including health services for local villagers[67]. Environmental Responsibility - The company has six pharmaceutical factories in Beijing, with a total wastewater discharge of 21.8 million tons and no exceedance of discharge standards[70]. - The company has implemented environmental protection measures, ensuring that wastewater and waste gas emissions meet local standards[72]. Financial Reporting and Accounting Practices - The financial statements are prepared based on the accrual basis of accounting, in accordance with the accounting standards issued by the Ministry of Finance[135]. - The company has a continuous operating basis for its financial statements, ensuring ongoing business viability[136]. - The company applies the equity method for accounting treatment of investments in joint ventures[153]. - The company recognizes impairment losses for inventory when its cost exceeds its net realizable value[192].

2018 年第三季度报告 公司代码：600085 公司简称：同仁堂 北京同仁堂股份有限公司 2018 年第三季度报告 1 / 19 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 2018 年第三季度报告 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人高振坤、总经理刘向光、主管会计工作负责人冯智梅及会计机构负责人（会计主 管人员）吕晓洁保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 一、 重要提示 2.1 主要财务数据 3 / 19 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年 度末增减(%) 总资产 20,264,951,620.80 18,708,132,920.39 8.32 归属于上市公司股东 ...

1 / 126 2018 年半年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 2018 年半年度报告 公司代码：600085 公司简称：同仁堂 北京同仁堂股份有限公司 2018 年半年度报告 无 六、 前瞻性陈述的风险声明 □适用 √不适用 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生产经营构成实质性影响的重大风险。公司在本报告中详细描述公司所 面临的政策风险、市场风险、原材料风险等，敬请投资者予以关注，详见本报告第四节"经营情 况的讨论与分析"中"可能面对的风险"部分。 十、 其他 □适用 √不适用 2 / 126 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人董事长高振坤、总经理刘向光、主管会计工作负责人冯智梅及会计机构负责人（会 计主管人员）吕晓洁声明：保证半年度报 ...

Financial Performance - In 2017, the company achieved a total operating revenue of CNY 13,375,966,344.01, representing a year-on-year increase of 10.63% compared to CNY 12,090,740,122.20 in 2016[20] - The net profit attributable to shareholders of the listed company for 2017 was CNY 1,017,381,549.82, which is a 9.02% increase from CNY 933,165,391.02 in 2016[20] - The company's operating cash flow net amount reached CNY 1,448,915,162.62, marking a significant increase of 38.55% from CNY 1,045,766,482.62 in the previous year[20] - As of the end of 2017, the total assets of the company amounted to CNY 18,708,132,920.39, reflecting a 9.66% increase from CNY 17,060,010,744.79 at the end of 2016[20] - The company's net assets attributable to shareholders reached CNY 8,416,085,767.07, which is a 7.99% increase from CNY 7,793,476,928.45 in 2016[20] - The basic earnings per share for 2017 was CNY 0.742, up 9.12% from CNY 0.680 in 2016[21] - The weighted average return on equity for the company was 12.55% in 2017, slightly increasing from 12.51% in 2016[21] Cash Flow and Investments - The net cash flow from operating activities increased by 38.55% to CNY 1.45 billion compared to the previous year[61] - The net cash flow from investment activities was negative at CNY 721.34 million, worsening from the previous year's negative CNY 530.99 million[61] - Investment income increased by 55.01% year-on-year, mainly due to the performance growth of affiliated enterprises[64] - The company reported a decrease in cash and cash equivalents by 94.67% to CNY 56.91 million compared to the previous year[61] - The net increase in cash and cash equivalents decreased by 94.67% compared to the same period last year, primarily due to reduced cash flows from investment and financing activities[62] Market Expansion and Product Development - The company has expanded its retail presence, establishing 700 retail outlets by the end of the reporting period, enhancing its market reach and brand visibility[34] - The company’s product lineup includes over 400 traditional Chinese medicine products, showcasing its extensive product range and brand strength[34] - The company is actively pursuing internet sales initiatives and has established dedicated product counters to enhance customer engagement and sales channels[31] - The company’s subsidiary, Beijing Tongrentang Guoyao Co., Ltd., has achieved business coverage in 21 countries and regions, promoting traditional Chinese medicine internationally[33] - The company successfully completed clinical trials for Ba Jitian oligosaccharide capsules and Shen Dan active blood capsules, providing robust data support for market promotion[40] - The company is exploring online and offline sales channels to enhance product distribution efficiency[86] Research and Development - Research and development expenses totaled CNY 218.97 million, representing 1.64% of operating revenue[57] - The R&D investment in the "Bajitian Sugar Capsules" was RMB 390.47 million, showing a decrease of 64.04% compared to the same period last year[79] - The "Zhen Dan Huoxue Capsules" R&D investment was RMB 176.93 million, down by 30.87% year-on-year[79] - The R&D investment in "Traditional Chinese Medicine Concentration and Volatile Oil Extraction" is ongoing, with a cumulative investment of RMB 3,690.93 million[83] Corporate Governance and Compliance - The company has maintained a stable governance structure with independent directors ensuring compliance and oversight[153] - The company has not faced any penalties from securities regulatory authorities in the past three years[161] - The internal control self-assessment report was disclosed on March 31, 2018, with no significant deficiencies reported during the period[176] - The audit report confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2017[184] Shareholder Information - The controlling shareholder, China Beijing Tong Ren Tang (Group) Co., Ltd., holds 719,308,540 shares, accounting for 52.45% of the total shares[141] - The company has a total of 719,308,540 shares locked up until November 30, 2017, as part of a voluntary commitment by the controlling shareholder[114] - The top ten shareholders include Anbang Property & Casualty Insurance Co., Ltd. with 72,655,829 shares (5.30%) and Harmony Health Insurance Co., Ltd. with 57,340,842 shares (4.18%)[141] Environmental Compliance - The company has implemented environmental protection measures, including the installation of air quality improvement equipment, to comply with local regulations[132] - The company has maintained compliance with local environmental standards for wastewater and air emissions across its production facilities[134] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% driven by new product launches and market expansion strategies[152] - The company aims to enhance its online sales platform, targeting a 30% increase in e-commerce revenue by the end of the next fiscal year[152] - The company plans to invest 100 million yuan in research and development for new technologies in traditional medicine[152]

北京同仁堂股份有限公司 2018 年第一季度报告 1 / 17 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 6 | 2018 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2018 年第一季度报告 1.2 公司全体董事出席董事会审议季度报告。 公司代码：600085 公司简称：同仁堂 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | 273.50 | | | 计入当期损益的政府补助，但与公 | 5,201,284.94 | | | 司正常经营业务密切相关，符合国 | | | | 家政策规定、按照一定标准定额或 | | | | 定量持续享受的政府补助除外 | | | | 除上述各项之外的其他营业外收入 | -62,503.96 | | | 和支出 | | | 3 / 1 ...

2017 年第三季度报告 公司代码：600085 公司简称：同仁堂 北京同仁堂股份有限公司 2017 年第三季度报告 1 / 19 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 7 | 2017 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人高振坤、总经理刘向光、主管会计工作负责人冯智梅及会计机构负责人（会计主 管人员）吕晓洁保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | 年初至报告期末金额 | 说明 | | --- | --- | --- | --- | | | （7－9 月） ...

2017 年半年度报告 公司代码：600085 公司简称：同仁堂 北京同仁堂股份有限公司 2017 年半年度报告 1 / 136 2017 年半年度报告 重要提示 无 六、 前瞻性陈述的风险声明 □适用 √不适用 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生产经营构成实质性影响的重大风险。公司在本报告中详细描述公司所 面临的政策风险、市场风险、原材料风险等，敬请投资者予以关注，详见本报告第四节"经营情 况的讨论与分析"中"可能面对的风险"部分。 十、 其他 □适用 √不适用 2 / 136 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人董事长高振坤、总经理刘向光、主管会计工作负责人冯智梅及会计机构负责人（会 计主管人员）吕晓洁声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期 ...